Gulf Pharmaceutical Industries
AADX:JULPHAR0.92
AED
-0.02
(-2.45%)
Gulf Pharmaceutical Industries
ADX:JULPHAR
(Abu Dhabi Securities Exchange)
Recent
price
0.92
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based pharmaceutical and biotechnology company engaged in the research, development, manufacturing, marketing, and distribution of branded generic pharmaceuticals, biosimilars, active pharmaceutical ingredients, and consumer healthcare products. Founded in 1980 and headquartered in Ras Al Khaimah, United Arab Emirates, the company operates through distinct therapeutic and commercial business units. Its comprehensive product portfolio includes: anti-infectives and antibiotics, encompassing penicillins, cephalosporins, and broad-spectrum antimicrobial agents; diabetes care and endocrinology therapeutics, featuring recombinant human insulin crystals, biosimilar insulin formulations marketed under the Jusline brand, and oral hypoglycemic drugs; dermatology and wound management solutions, led by moist exposed burn ointments under the MEBO brand, topical corticosteroids, and antibacterial creams; cardiovascular and metabolic medications, including antihypertensive agents, lipid-regulating statins, and antiplatelet drugs; gastrointestinal treatments, such as proton pump inhibitors, antacids, and antiemetic agents; central nervous system therapies, including analgesics, antipyretics, and neurological formulations; respiratory medicines, comprising antihistamines, bronchodilators, and mucolytics; consumer healthcare products, including multivitamins, dietary supplements, and pediatric formulations; and sterile medical consumables, intravenous fluids, and specialized injectables. Julphar distributes its products to government healthcare authorities, hospitals, clinics, retail pharmacies, and commercial wholesalers across more than 40 countries throughout the Middle East, North Africa, Sub-Saharan Africa, Central Asia, and Eastern Europe, supported by manufacturing facilities located in the United Arab Emirates, Saudi Arabia, and Ethiopia. In recent major developments, the company has been advancing its multi-year Vision 2030 transformation strategy focused on core pharmaceutical manufacturing, specialty therapeutic expansion, and geographical scale. As part of its strategic portfolio realignment, Julphar completed the divestment of its retail pharmacy equity interest in Planet Pharmacies to redeploy capital into high-growth biopharmaceuticals and injectables. Additionally, the company entered into strategic in-licensing and commercial partnerships with international biopharmaceutical companies to commercialize specialized oncology, immunology, and critical care therapies across the GCC region, while modernizing its dedicated biotechnology facilities to increase production capacity for recombinant insulin crystals, launching newly registered generic formulations, and executing balance sheet optimization initiatives to strengthen operational cash flow.